TP53 and neoplasm: Key genetic alterations, including TP53 (64%), RB1 (14%), KRAS (22%), BRAF (63% in colorectal NECs), and MYC amplifications (51%), fuel aggressive tumor behavior and resistance to therapy [51,77,102].